Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

on behalf of the CheckMate 025 investigators

doi:10.1016/j.eururo.2017.12.016

Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

on behalf of the CheckMate 025 investigators

Université Paris-Sud
University of Texas MD Anderson Cancer Center
Dana-Farber/Harvard Cancer Center
Roswell Park Cancer Institute
Johns Hopkins University
University of Texas Southwestern Medical Center
Stanford University
Fred Hutchinson Cancer Research Center
Vanderbilt University
Northwestern University
Fondazione IRCCS Istituto Nazionale dei Tumori
Hospital Universitario 12 de Octubre
Westmead Hospital
Aarhus University
Helsinki University Hospital
Swansea University
University of Duisburg-Essen
Chiba Cancer Center
Bristol-Myers Squibb
Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

The publisher regrets that an error occurred during the preparation of Figure 1A for final publication. The position of some of the point estimates and the size of the bars representing the confidence intervals were incorrect. An updated version of the article with the correct version of Figure 1A was published online in December 2017. For reference, both the corrected figure that is currently online and the incorrect version of Figure 1A that was published online and in print are shown below.

Original language	English
Pages (from-to)	e116-e118
Journal	European Urology
Volume	73
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2017.12.016
State	Published - Apr 2018

Access to Document

10.1016/j.eururo.2017.12.016

Fingerprint

Dive into the research topics of 'Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))'. Together they form a unique fingerprint.

Cite this

on behalf of the CheckMate 025 investigators (2018). Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010)). European Urology, 73(4), e116-e118. https://doi.org/10.1016/j.eururo.2017.12.016

@article{a9b2812f2a9442f3a875137f77426c65,

title = "Erratum to {\textquotedblleft}CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma{\textquotedblright} [Eur Urol 2017;72:962{\textendash}71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))",

abstract = "The publisher regrets that an error occurred during the preparation of Figure 1A for final publication. The position of some of the point estimates and the size of the bars representing the confidence intervals were incorrect. An updated version of the article with the correct version of Figure 1A was published online in December 2017. For reference, both the corrected figure that is currently online and the incorrect version of Figure 1A that was published online and in print are shown below.",

author = "\{on behalf of the CheckMate 025 investigators\} and Bernard Escudier and Padmanee Sharma and McDermott, \{David F.\} and Saby George and Hammers, \{Hans J.\} and Sandhya Srinivas and Tykodi, \{Scott S.\} and Sosman, \{Jeffrey A.\} and Giuseppe Procopio and Plimack, \{Elizabeth R.\} and Daniel Castellano and Howard Gurney and Frede Donskov and Katriina Peltola and John Wagstaff and Gauler, \{Thomas C.\} and Takeshi Ueda and Huanyu Zhao and Waxman, \{Ian M.\} and Motzer, \{Robert J.\}",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2018",

month = apr,

doi = "10.1016/j.eururo.2017.12.016",

language = "English",

volume = "73",

pages = "e116--e118",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "4",

}

on behalf of the CheckMate 025 investigators 2018, 'Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))', European Urology, vol. 73, no. 4, pp. e116-e118. https://doi.org/10.1016/j.eururo.2017.12.016

Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010)). / on behalf of the CheckMate 025 investigators.
In: European Urology, Vol. 73, No. 4, 04.2018, p. e116-e118.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum to “CheckMate 025 Randomized Phase 3 Study

T2 - Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

AU - on behalf of the CheckMate 025 investigators

AU - Escudier, Bernard

AU - Sharma, Padmanee

AU - McDermott, David F.

AU - George, Saby

AU - Hammers, Hans J.

AU - Srinivas, Sandhya

AU - Tykodi, Scott S.

AU - Sosman, Jeffrey A.

AU - Procopio, Giuseppe

AU - Plimack, Elizabeth R.

AU - Castellano, Daniel

AU - Gurney, Howard

AU - Donskov, Frede

AU - Peltola, Katriina

AU - Wagstaff, John

AU - Gauler, Thomas C.

AU - Ueda, Takeshi

AU - Zhao, Huanyu

AU - Waxman, Ian M.

AU - Motzer, Robert J.

PY - 2018/4

Y1 - 2018/4

N2 - The publisher regrets that an error occurred during the preparation of Figure 1A for final publication. The position of some of the point estimates and the size of the bars representing the confidence intervals were incorrect. An updated version of the article with the correct version of Figure 1A was published online in December 2017. For reference, both the corrected figure that is currently online and the incorrect version of Figure 1A that was published online and in print are shown below.

AB - The publisher regrets that an error occurred during the preparation of Figure 1A for final publication. The position of some of the point estimates and the size of the bars representing the confidence intervals were incorrect. An updated version of the article with the correct version of Figure 1A was published online in December 2017. For reference, both the corrected figure that is currently online and the incorrect version of Figure 1A that was published online and in print are shown below.

UR - https://www.scopus.com/pages/publications/85039866578

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000427486600011&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.eururo.2017.12.016

DO - 10.1016/j.eururo.2017.12.016

M3 - Comment/debate

C2 - 29306512

SN - 0302-2838

VL - 73

SP - e116-e118

JO - European Urology

JF - European Urology

IS - 4

ER -

on behalf of the CheckMate 025 investigators. Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010)). European Urology. 2018 Apr;73(4):e116-e118. doi: 10.1016/j.eururo.2017.12.016

Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

Abstract

Access to Document

Other files and links

Fingerprint

Cite this